Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA by Sidhu, Navdeep S. et al.
research papers
Acta Cryst. (2014). D70, 1321–1335 doi:10.1107/S1399004714002739 1321




Structure of sulfamidase provides insight into the
molecular pathology of mucopolysaccharidosis IIIA
Navdeep S. Sidhu,a,b Kathrin
Schreiber,a Kevin Pro¨pper,b‡
Stefan Becker,c Isabel Uso´n,d,e
George M. Sheldrick,b Jutta
Ga¨rtner,a Ralph Kra¨tznera* and
Robert Steinfelda*
aDepartment of Neuropediatrics, Faculty of
Medicine, University of Go¨ttingen, Robert-
Koch-Strasse 40, 37075 Go¨ttingen, Germany,
bDepartment of Structural Chemistry, Institute of
Inorganic Chemistry, University of Go¨ttingen,
Tammannstrasse 4, 37077 Go¨ttingen, Germany,
cMax Planck Institute for Biophysical Chemistry,
Am Fassberg 11, 37077 Go¨ttingen, Germany,
dInstituto de Biologia Molecular de Barcelona
(IBMB–CSIC), Barcelona Science Park, Baldiri
Reixach 15, 08028 Barcelona, Spain, and
eInstitucio Catalana de Recerca i Estudis Avan-
cats (ICREA), Spain
‡ Deceased 4 July 2013.
Correspondence e-mail: rkraetz@gwdg.de,
rsteinfeld@med.uni-goettingen.de
Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),
a fatal childhood-onset neurodegenerative disease with mild
facial, visceral and skeletal abnormalities, is caused by an
inherited deficiency of the enzyme N-sulfoglucosamine
sulfohydrolase (SGSH; sulfamidase). More than 100 muta-
tions in the SGSH gene have been found to reduce or
eliminate its enzymatic activity. However, the molecular
understanding of the effect of these mutations has been
confined by a lack of structural data for this enzyme. Here, the
crystal structure of glycosylated SGSH is presented at 2 A˚
resolution. Despite the low sequence identity between this
unique N-sulfatase and the group of O-sulfatases, they share a
similar overall fold and active-site architecture, including a
catalytic formylglycine, a divalent metal-binding site and a
sulfate-binding site. However, a highly conserved lysine in O-
sulfatases is replaced in SGSH by an arginine (Arg282) that is
positioned to bind the N-linked sulfate substrate. The
structure also provides insight into the diverse effects of
pathogenic mutations on SGSH function in mucopolysacchar-
idosis type IIIA and convincing evidence for the molecular
consequences of many missense mutations. Further, the
molecular characterization of SGSH mutations will lay the
groundwork for the development of structure-based drug
design for this devastating neurodegenerative disorder.
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Mucopolysaccharidoses (MPS) are a group of recessively
inherited lysosomal storage disorders caused by a deficiency of
enzymes involved in the metabolic breakdown of glycosamino-
glycans (GAGs; also known as mucopolysaccharides). GAGs
are unbranched polysaccharide chains consisting of repeating
disaccharide units that contain variable modifications. In the
cases of heparin and heparan sulfate, the degree of O- and N-
sulfation is crucial for the biological function of these GAGs
(Turnbull et al., 2010).
At least 11 different enzyme deficiencies are currently
known to be associated with the lysosomal storage of glyco-
aminoglycans (Ballabio & Gieselmann, 2009). The inherited
MPS disorders show multiple clinical symptoms such as facial
dysmorphism, skeletal dysplasia, hepatosplenomegaly and
variable signs of neurodegeneration (Clarke, 2008). In the
subtypes III of mucopolysaccharidoses, also called Sanfilippo
syndrome, signs of neurodegeneration are the initial symp-
toms and comprise of hyperactivity, developmental stagnation
and psychomotor regression (Valstar et al., 2010). Mucopoly-
saccharidosis type IIIA (MPS IIIA) is caused by the functional
defect of N-sulfoglucosamine sulfohydrolase (SGSH; also
known as sulfamidase, sulfamate sulfohydrolase and heparan
N-sulfatase; EC 3.10.1.1) and represents one of the most
frequent lysosomal storage diseases worldwide. Its incidence
ranges from 0.68 per 100 000 to 1.21 per 100 000 in European
countries (He´ron et al., 2011; Baehner et al., 2005).
SGSH belongs to the sulfatase family and catalyses the
cleavage of N-linked sulfate groups from the GAGs heparan
sulfate and heparin. The active site is characterized by the
amino-acid sequence motif C(X)PSR that is highly conserved
among most sulfatases from all species. The leading cysteine
is post-translationally converted to a formylglycine (FGly)
residue, which is crucial for the catalytic process (Dierks et al.,
1999, 2005; Daniele & Di Natale, 2001).
Currently, there is no effective therapy available for MPS
IIIA. Pathophysiological changes in the brain are the major
determinants of the clinical picture. However, intravenous
enzyme-replacement therapy is hampered by the very limited
ability of the enzyme to cross the blood–brain barrier. While
the structures of many O-sulfatases have been determined
(Boltes et al., 2001; Bond et al., 1997; Hernandez-Guzman et
al., 2003; Lukatela et al., 1998; Rivera-Colo´n et al., 2012; van
Loo et al., 2010), no structures are available for an N-sulfatase
such as SGSH. In addition, since SGSH shares only a very low
sequence identity (approximately 19–25%) with O-sulfatases
with known structures, understanding the molecular basis of
this lethal disease is incomplete (Perkins et al., 1999).
To understand the catalytic mechanism of human SGSH at
the molecular level and to gain insight into the functional
consequences of clinically relevant SGSH mutations, we
determined its crystal structure in two crystal forms to reso-
lutions of 2.00 and 2.40 A˚. We compare the structure of SGSH
as an enzyme cleaving N-linked sulfate groups with its closest
O-sulfatase homologues that hydrolyze O-linked sulfates
and discuss the structural consequences of clinically known
mutations. Our results reveal structural deviations of SGSH
fromO-sulfatases and disclose unique features of its substrate-
binding site.
2. Materials and methods
2.1. Protein expression and purification
The amino-acid sequence RSHHHHHH was introduced at
the C-terminus of the SGSH protein to facilitate purification.
Transfection of the modified SGSH cDNA and selection of
HEK 293 cells were performed as described previously
(Steinfeld et al., 2004). Recombinant protein samples of SGSH
were purified from the cell-culture supernatant. The medium
was cleared by centrifugation at 3000g and 4C for 60 min and
was then filtered with a 0.2 mm pore membrane. After adding
20 mM K2HPO4 pH 7.5, 0.5M NaCl, 40 mM imidazole, the
crude solution was loaded onto a HisTrap HP column (GE
Healthcare, Freiburg, Germany). Bound SGSH was eluted at
an imidazole concentration of 250 mM with a step gradient.
For crystallization, the purified SGSH fractions were pooled
and concentrated using a centrifugal filter (Millipore,
Schwalbach, Germany). The final protein solution contained
10 mg ml1 SGSH and was adapted to 10 mM Tris pH 7.5,
100 mM NaCl. Enzyme purity was checked using SDS–PAGE.
2.2. Protein crystallization
We obtained two different crystal forms of SGSH: a small-
cell (S) form and a large-cell (L) form. Both forms were
obtained using the sitting-drop vapour-diffusion method at
293 K. The S form was obtained in robotic crystallization
screening trials set up in 96-well Greiner plates using Tecan
Genesis RSP 150 and TTP Labtech Mosquito robots. The
reservoir and drop volumes were 100 and 0.1 ml, respectively.
The drop was prepared by mixing the protein solution with
the reservoir solution in a 1:1 ratio. Rod-shaped crystals of
maximum dimensions 20  20  50 mm grew over several
weeks in 25%(w/v) polyethylene glycol (PEG) 3350, 200 mM
MgCl2, 100 mM HEPES buffer pH 7.5. The L form was
obtained during manual optimization trials, with rod-shaped
crystals of typical dimensions 50  50  350 mm, in 13%(w/v)
PEG 8000, 200 mM MgCl2, 100 mM bis-tris buffer pH 5.1.
2.3. Data collection
Native single-crystal X-ray diffraction data were collected
on the PXII beamline at the Swiss Light Source using mono-
chromatic radiation of wavelength 0.99989 A˚with a Pilatus 6M
detector, an oscillation range of 0.1 and an exposure time of
0.1 s. A total of 3600 images were collected for the S crystal
form, for which the space group was determined to be P21,
with unit-cell parameters a = 61.4, b = 107.9, c = 79.8 A˚,
 = 104.1; 1800 images were collected for the L crystal form,
which also crystallized in space group P21, with an approxi-
mately four times larger unit cell: a = 103.0, b = 211.6,
c = 108.4 A˚,  = 102.7. Data reduction was performed using
the programs XDS (Kabsch, 2010) and XPREP (Sheldrick,
2012). Resolution limits for the small and large cells were set
at 2.00 and 2.40 A˚, respectively, based on self-correlation
coefficients (Karplus & Diederichs, 2012) of approximately
65% for each. Table 1 lists the data-collection and refinement
statistics.
2.4. Structure solution and refinement
The crystal structure of Pseudomonas aeruginosa sulfatase
(Boltes et al., 2001; PDB entry 1hdh), which shares a structure-
based sequence identity of approximately 22% with SGSH,
was used as the basis from which to derive search-model
fragments for molecular replacement (MR) in the small cell,
as implemented in the program ARCIMBOLDO (Rodrı´guez
et al., 2009), and to combine the outcome to design an optimal
MR search model. An initial rotation–translation solution
with two incomplete monomers in the asymmetric unit was
found that was clearly discriminated by MR figures of merit
from all other solutions. However, attempts to refine this
solution as such failed. Systematic attempts were made to
improve the solution by disassembling parts of the model
based on structure-based sequence alignments with close
homologues, rigid-body refinement of rigid groups in Phaser
(McCoy et al., 2007) as part of the CCP4 suite of programs
(Winn et al., 2011), and low-resolution rigid-body and jelly-
body refinement in REFMAC (Winn et al., 2011; Murshudov
et al., 1997, 2011), gradually increasing the resolution. The
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program SCWRL4 (Krivov et al., 2009) was initially used to
model and test secondary-structure-based side-chain rota-
mers. The criteria monitored included the log-likelihood gain
and the fit of the model to the electron density. A significantly
incomplete but refinable model was finally obtained. For the
Rfree set for cross-validation of the structure models, 5% of
all reflections were put aside randomly for the small cell;
SFTOOLS (Winn et al., 2011),MTZ2HKL (Grune, 2008) and
XPREP were used to place aside, in 21 thin shells (2.45–
48.9 A˚), 8462 (4.8%) of all reflections for the large cell.
A partial structural model for the S crystal form was then
used as a search model to solve the structure of the L form
using Phaser. This latter cell contained eight molecules in
the asymmetric unit. Density modification with NCS averaging
over the small-cell and large-cell crystal forms could now be
used with the program DMMULTI as part of CCP4 (Winn et
al., 2011; Cowtan, 1994), facilitating structure building in the S
form. Manual building could subsequently be complemented
by piecemeal corrections derived from automatic chain tracing
using the program Buccaneer as part of CCP4 (Winn et al.,
2011; Cowtan, 2006). A completed model was then used to
re-solve and refine the large-cell structure. Model building
was peformed using Coot (Emsley et al., 2010). Maximum-
likelihood refinement of model coordinates against the
working set data was performed using REFMAC5.5 with local
NCS restraints. Water molecules were added automatically or
manually in Coot. Waters were deleted manually if the refined
density was weak, if the B factor refined to values exceeding
80 A˚2 or if the waters were too close to neighbouring atoms
or too distant from the protein. In the final refinement
macrocycles, H atoms were added in riding positions and TLS
parameters were refined (Murshudov et al., 2011). The final
Rfree (Bru¨nger, 1992) and Rwork are 22.99 and 19.20%,
respectively, for the small cell and 24.47 and 21.57%, respec-
tively, for the large cell. SGSH monomer superposition
r.m.s.d.s were calculated using Indonesia (Madsen et al., 2005);
those for the dimer were calculated using LSQKAB (Kabsch,
1976). Figures were drawn using PyMOL (Mura et al., 2010)
or an in-house program (NSS, unpublished work). Accessible
surface area was calculated using the PISA server (Krissinel &
Henrick, 2007). Normalized accessible surface area (NASA)
per atom per residue was calculated by setting the accessible
surface area per atom per residue for Lys490 as 100 and
expressing the values for other residues in relation to this as
a percentage. A model of the substrate was docked using the
program AutoDock Vina (Trott & Olson, 2010).
2.5. SGSH activity assay
SGSH activities were determined by a fluorometric assay
as described previously (Karpova et al., 1996). The enzymatic
activity of SGSH was measured in a two-step reaction: 4-
methylumbelliferyl--d-N-sulfoglucosaminide (MU-GlcNS)
is desulfated by SGSH to become a substrate for -gluco-
sidase, which converts 4-methylumbelliferyl--d-N-
sulfoglucosamine (MU-Glc) to methylumbelliferone (MU),
which is a fluorescent compound. The amount of MU can be
quantified at wavelengths of 360 nm (excitation) and 460 nm
(emission) using an external MU standard curve. Briefly,
SGSH from a stock solution (0.8 mg ml1) was diluted 1:100
with water containing NaCl (0.9%) and BSA (0.2%). 10 ml of
this SGSH solution was gently mixed with 20 ml substrate
buffer (14.3 mM sodium barbital, 14.3 mM sodium acetate pH
6.5, 0.7% NaCl, 2.28 mg ml1 MU-GlcN) and 10 ml inhibitor
solution, which was prepared using KH2PO4 or Na2SO4 in
water to reach final concentrations of 500, 250, 100, 50, 10, 5,
2.5, 1 or 0.5 mM SO4
2 or PO4
3 in the mixture. As a control for
full enzymatic activity, 10 ml pure water was added instead of
the inhibitor solution. The reaction mixture was incubated for
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Table 1
Data-collection and refinement statistics.
The number of atoms is the occupancy sum; B factors are occupancy-weighted
means. Solvent atoms were excluded when calculating the mean B factors for
individual chains.
Crystal form S L
PDB code 4mhx 4miv
Space group P21 P21
Unit-cell parameters
a (A˚) 61.4 103.0
b (A˚) 107.9 211.6
c (A˚) 79.8 108.4
 () 104.1 102.7
Data collection
Wavelength (A˚) 0.99989 0.99989




No. of reflections measured 452472 599199
No. of unique reflections 67940 174779
Multiplicity† 6.65 (6.38) 3.41 (3.45)
Rmerge† 0.0886 (0.6539) 0.0702 (0.4723)
R† 0.0500 (0.5504) 0.0594 (0.4917)
Completeness† (%) 99.9 (99.8) 99.3 (98.7)
Mean I/(I)† 11.20 (1.85) 11.03 (2.08)
Refinement
Resolution limit (A˚) 44.3–2.00 48.85–2.40
Rfree (No. of reflections) 0.2299 (3447) 0.2447 (8462)
Rwork 0.1920 0.2157
Total No. of reflections (working set) 64437 166273
Solvent content (%) 45.9 53.0
No. of molecules in the asymmetric unit 2 8
No. of non-H atoms refined 7968 31122
No. of water molecules refined 205 475
Mean B factors (A˚2)
Protein atoms 44.7 64.5
Backbone atoms 43.5 64.2
Side-chain atoms 45.9 64.8
Water atoms 39.0 37.6
Chain A 45.5 48.9
Chain B 43.9 44.1
Chain C — 48.3
Chain D — 44.9
Chain E — 85.5
Chain F — 75.8
Chain G — 79.6
Chain H — 93.0
R.m.s.d.s from ideal geometry
Bond lengths (A˚) 0.0125 0.0028
Bond angles () 1.564 0.683
Ramachandran statistics
Favored region (%) 97.1 (933/961) 97.2 (3727/3835)
Allowed region (%) 99.8 (959/961) 99.7 (3823/3835)
Outlier region (%) 0.21 (2/961) 0.31 (12/3835)
† Values in parentheses are for the outermost resolution shell.
2 h in a 96-well plate at 37C and shaken at 300 rev min1.
Subsequently, 6 ml Pi/Ci buffer (0.4M sodium phosphate,
0.2M citrate pH 6.7) and 10 ml -glucosidase (10 U ml1,
0.2% BSA) were added. After incubation for 24 h at 37C,
150 ml stop buffer (0.175M glycine/Na2CO3) was added,
followed by fluorometric measurement of enzymatic
activity.
3. Results
Full-length human SGSH was expressed
in HEK 293 cells and was purified from
the cell-culture supernatant. A two-
residue C-terminal linker followed by a
six-His tag (residues 503–510) was used
to assist in purification of the recombi-
nantly produced enzyme.
Two crystal forms of glycosylated
SGSH were grown at different pH
values. The crystal form grown at pH 7.5
is designated crystal form S (small unit
cell). The structure of this form was
refined to 2.00 A˚ resolution. The form
grown at pH 5.1 is designated crystal
form L (large unit cell). Its structure was
refined to 2.40 A˚ resolution. There are
two molecules in the asymmetric unit of
crystal form S and eight molecules in
that of form L. The enzyme appears to
exist as a homodimer in both crystal
forms.
3.1. Model quality
For crystal form S, continuous
electron density of good quality was
observed for both molecules in the
asymmetric unit; residues 22–504 were
modelled in chain A and residues 22–
503 in chain B. For crystal form L, the
quality of the electron density varied
significantly for the eight molecules in
the asymmetric unit, with better density
for approximately half of the molecules
(chains A–D); the number of modelled
residues ranged from 485 (residues
21–505) in chain A to 481 (residues 22–
502 with residues 185–186 unmodelled)
in chain F. Since the protein ’/ angles
were not restrained during refinement,
they serve as an indicator of model
quality. The Ramachandran plot
(Lovell et al., 2003; Ramakrishnan &
Ramachandran, 1965) values and
data-collection and refinement statistics
are listed in Table 1. Asp94 is an outlier
in all ten chains in the two crystal forms, but lies in good
density.
3.2. Structure of the SGSH monomer
The crystal structure of glycosylated human SGSH was
solved using molecular replacement. The monomeric enzyme
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Figure 1
Schematic representations of the SGSH structure. (a) Mapping of SGSH primary and secondary
structures. -Strands, red arrows; -helices, blue striped rectangles; 310-helices, violet rectangles; the
two disulfide bridges are shown as orange lines and the four glycosylated asparagines as yellow filled
circles. Functionally important residues (active site and glycosylation sites) are shown in red; some
of the residues at the dimer interface are shown in blue. The phenotype of the missense mutation
sites is indicated below the sequence as follows: early-onset disease (E), red; intermediate-onset (I),
orange; late-onset (L), blue; phenotype not reported in the literature (N), grey. (b) Topology
diagram (not drawn to scale). Colour coding is similar to that in Fig. 1(a), with -helices shown as
blue cylinders and the N-terminus and C-terminus as blue and red circles, respectively. Divalent
metal-binding residues are labelled M1 (Asp31, Asp32), M2 (FGly70) and M3 (Asp273, Asn274).
Secondary-structure elements are named as indicated in the main text.
subunit comprises of two domains, each centred on a -sheet:
a large N-terminal domain (domain 1) and a smaller C-term-
inal domain (domain 2), as is typical for the sulfatase fold.
There are 14 -strands, 13 -helices and six 310-helices (T1–
T6) in total [Fig. 1; classification based on Kabsch & Sander
(1983) as implemented in PROCHECK (Winn et al., 2011)].
Domain 1 has an / form. Its core is formed by a mixed
-sheet consisting of eight -strands, all except one of which
are parallel, with nine decorating -helices on both sides of the
-sheet (Fig. 1b). One of the helices is 30 residues in length
(helix 7). The core of domain 2 is formed by a four-stranded
antiparallel -sheet, with four surrounding -helices, followed
by a C-terminal extension consisting of a small two-stranded
antiparallel -sheet. The enzyme contains two intrasubunit
disulfide bonds. One of these (Cys183–Cys194) stabilizes a
long, loop-rich segment (5–7; residues 177–229) in domain
1. The second (Cys481–Cys495) ties the C-terminal extension
to a proximal loop in domain 2 (Fig. 2a). Electron density
corresponding to glycosylated residues was observed at
Asn41, Asn151, Asn264 and Asn413, in agreement with four
of the five glycosylation sites previously reported (Di Natale et
al., 2001); no glycosylation could be detected at Asn142. There
are four cis-peptide bonds in both chains, between prolines
and the preceding Gly127, Asp179, Ala482 and Ser492; all of
them lie in good density.
Two SGSH monomers associate noncovalently to form a
‘butterfly-shaped’ homodimer (Fig. 2b), burying approxi-
mately 10.3% of the accessible surface area of each subunit.
3.3. SGSH shows low structural flexibility
Since the SGSH structure was determined
in two crystal forms, S and L, we could use
the ten crystallographically independent
monomers of SGSH to assess the structural
flexibility of the enzyme under two different
crystallization conditions. The enzyme
subunits display a low rigid-body structural
flexibility in the S form (C r.m.s.d. of 0.20 A˚
between the two chains, with NCS
restraints) as well as the L form (r.m.s.d.
ranging from 0.10 to 0.17 A˚, with NCS
restraints). To investigate the mobility at the
dimer interface, all five homodimers were
superimposed based on one of the subunits
in each dimer. The relative orientation of
the dimer subunits in the L form differs from
that in the S form by 2.6–3.0, indicating that
the dimer interface is slightly flexible,
possibly owing to crystal packing.
3.4. The active site and inhibition of SGSH
by sulfate and phosphate
The consensus active site lies in domain
1 in a narrow pocket at the bottom of a
surface cleft (Fig. 2c) and close to the end of
the first -strand. Electron density consis-
tent with the position of a divalent metal
ion in O-sulfatases was interpreted as Ca2+
based on bond-valence calculations (Mu¨ller
et al., 2003). The metal ion is coordinated
in a distorted, approximately octahedral
arrangement by O atoms from the side
chains of residues Asp31, Asp32, Asp273
and Asn274 and the phosphorylated
FGly70, as shown in Fig. 2(d). A schematic
overview of interactions in the active site is
given in Fig. 3(a).
Since a clear differentiation between
phosphate and sulfate as the species bound
to FGly70 was not feasible based only on
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Figure 2
Three-dimensional structure of SGSH. (a) Monomer. The approximate locations of domains 1
and 2 are shown (square brackets), with -sheets in domain 2 labelled 2 and 3. -Strands are
shown in red, -helices in blue and loops in yellow. Cystine bridges are shown in orange
(Cys#1, 183–194; Cys#2, 481–495). The N-terminus (N) is shown as a blue ball and the
C-terminus (C) as an orange ball. The formylglycine (FGly) 70 side chain is shown as a stick
model in standard colours. The Ca2+ ion is shown as a grey ball. Glycosylation sites (‘NAG-’
followed by the asparagine residue number) are shown as green sticks. (b) Dimer. The dimer
noncrystallographic symmetry axis lies vertically in the plane of the paper, with subunit
centroids in the approximate paper plane on either side of it. FGly70, cystine bridges and
glycosylations are shown as orange stick models. Other representations are as in Figs. 1 and
2(a).
the electron density, we made quantitative measurements of
the inhibitory effects of phosphate and sulfate on SGSH (Fig.
3b). The IC50 values determined for phosphate and sulfate
were 1 and 5 mM, respectively, indicating preferential phos-
phate binding. Since 20 mM K2HPO4 was present in the
purification buffer, the electron density joined to FGly70 was
modelled as a phosphate group. This crucial catalytic residue is
stabilized by multiple interactions. The bridging O atom
between C of FGly70 and the phosphate moiety coordinates
Ca2+, while the hydroxyl O atom interacts with the side chains
of Arg74, Lys123 and His125. The phosphate is further
stabilized by interactions between its distal O atoms and Ca2+,
and the side chains of Lys123, His181 and Arg282.
3.5. Homology of SGSH with O-sulfatases
A Protein Data Bank (PDB) database search revealed only
low sequence identities with known structures of O-sulfatases,
ranging between 19 and 25% (Table 2). Five of these O-
sulfatases catalyze the hydrolysis of an S—O bond in sulfate
esters; the sixth is a phosphonate monoester hydrolase from
Burkholderia caryophylli PG2952 (BcPMH) which acts on a
broader range of substrates, including phosphate monoesters,
diesters and triesters, phosphonate monoesters, sulfate
monoesters and sulfonate monoesters (van Loo et al., 2010).
Fig. 4 shows an overlay of the SGSH main chain (red) with five
of these closest O-sulfatase homologues. The SGSH structure
shares with other N- and O-sulfatases the conserved fold of
a large central -sheet decorated by -helices on both sides.
Structural differences are smallest in this area, while the loops
protruding from this region, and the C-terminal domain,
display a significant variability among these sulfatases. The
active site lies at the boundary of the two regions. The entry to
the active site traverses the unconserved region, presumably
reflecting the structural differences between the different
substrates of these enzymes. Although the catalytic centres of
these sulfatases show a high degree of
conservation; there are a few exceptions
(Table 2), including the replacement of
Arg282 in SGSH by a lysine in the O-
sulfatase homologues.
4. Discussion
In the current study, we describe the first
structure of sulfamidase, deficient activity
of which causes the disease Sanfilippo A
syndrome (also known as mucopoly-
saccharidosis IIIA). To our knowledge, it is
also the first reported structure of a sulfatase
that breaks an S—N sulfamate bond rather
than an S—O sulfate-ester bond. The
overall structure of the N-sulfatase SGSH
subunit displays a characteristic sulfatase
fold that is a member of the /-hydrolase
fold family (Nardini & Dijkstra, 1999). The
enzyme forms a homodimer in both of the
two crystal forms for which structures were
solved, with a calculated molecular weight
of the mature unglycosylated subunit of
55 kDa. A comparison of all ten indepen-
dent subunits in two different crystal forms
of SGSH revealed low structural flexibility
within the subunit. However, the dimer
interface is slightly flexible, displaying a
rotation of up to 3.0 in the two crystal
forms.
4.1. Active site
Residues neighbouring FGly70 in the
active site are generally highly conserved
between the N-sulfatase SGSH and the
closest O-sulfatase homologues for which
structures are available, excluding BcPMH.
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Figure 2 (continued)
(c) A short tunnel from a surface cleft leads to the active site. The inset on the left shows an
enlargement of the boxed area. The two dimer subunits are shown in blue and cyan, FGly is
shown as yellow spheres or sticks and glycosylations are shown as green sticks. (d) Active site
as viewed from its entry (stick models; the major interactions shown are described in the main
text).
Notable exceptions are Arg282 (SGSH; discussed below),
which is replaced by a lysine in these O-sulfatases, and the
Ca2+-binding residue Asn274, which is replaced by a glutamine
in ES. All ten important active-site residues in SGSH are
conserved in the closest homologous sequences from diverse
vertebrates and invertebrates that are tentatively annotated as
SGSHs (Supplementary Fig. 1).
An in silico prediction was made that histidines are not
involved in the active site of sulfamidase from Flavobacterium
heparinum, thus distinguishing it from the active site of
O-sulfatases (Myette et al., 2009). In human SGSH, both
histidines are involved in active-site interactions, as in
O-sulfatases. However, a high degree of structural variability
between SGSH and O-sulfatases begins in the immediate
neighbourhood of the active-site
residues, specifically in the short
tunnel leading to the active site
and its surrounding surface cleft.
This presumably enables SGSH
and O-sulfatases to accommodate
distinct substrates that undergo a
similar enzymatic reaction.
The crystallization conditions
contained Mg2+ rather than Ca2+
ions. The latter ion is assumed to
have bound to the enzyme intra-
cellularly during expression and
is the typical divalent cation for
sulfatases (Table 2 and references
therein). However, we are unable
to exclude the possibility that at




SGSH catalyzes the cleavage of
the S—N bond in N-sulfoglucos-
amine, desulfating the glycos-
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Figure 3
Active site and enzyme inhibition. (a) Schematic of the active-site region in SGSH. ACa2+ ion is coordinated by side-chain P atoms from Asp31, Asp32,
Asp273, Asn274 and the phosphorylated FGly70, which is in turn stabilized by interactions with the side chains of residues Arg74, Lys123, His125,
His181, Asp273 and Arg282. (b) Inhibition of SGSH acitivity by phosphate and sulfate. The IC50 of phosphate was determined to be 1 mM; the IC50 of
sulfate was 5 mM.
Table 2
Structurally equivalent active-site residues classified by (putative) function in SGSH and closely
homologous sulfatases with known atomic structures.
ASA, arylsulfatase A (also known as human lysosomal cerebroside-3-sulfate 3-sulfohydrolase; Lukatela et al.,
1998); ASB, arylsulfatase B (human lysosomal N-acetylgalactosamine-4-sulfate 4-sulfohydrolase (Bond et al.,
1997); PAS, arylsulfatase from P. aeruginosa (Boltes et al., 2001); ES, human oestrone/dehydroepiandrosterone
sulfatase (Hernandez-Guzman et al., 2003); GALNS, human lysosomal (N-acetyl)galactosamine-6-sulfatase
(Rivera-Colo´n et al., 2012); BcPMH, sulfatase/hydrolase from B. caryophylli PG2952 (van Loo et al., 2010).
Sequence identities were calculated for protein sequences using the PROMALS3D server (Pei et al., 2008) and
ClustalW2 (BcPMH; Goujon et al., 2010). R.m.s.d.s were calculated using Coot. Lys123 (SGSH numbering) and its
equivalent residues in homologues also participate in sulfate binding.
Enzyme SGSH PAS ASA ASB GALNS ES BcPMH
PDB code 4mhx 1hdh 1auk 1fsu 4fdi 1p49 2w8s
Sequence identity (%) 100 22.4 22.2 19.7 22.8 19.1 24.6
R.m.s.d. (A˚) (No. of residues) 0.00 (482) 2.17 (341) 2.21 (331) 2.18 (312) 1.97 (336) 1.95 (303) 1.98 (345)
Desulfation FGly70 FGly51 FGly69 FGly91 FGly79 FGly75 FGly57
Metal Ca2+ Ca2+ Mg2+ (Ca2+)† Ca2+ Ca2+ Ca2+ Fe
Metal binding Asp31 Asp13 Asp29 Asp53 Asp39 Asp35 Asp12
Asp32 Asp14 Asp30 Asp54 Asp40 Asp36 —
Asp273 Asp317 Asp281 Asp300 Asp288 Asp342 Asp324
Asn274 Asn318 Asn282 Asn301 Asn289 Gln343 His325
FGly binding Arg74 Arg55 Arg73 Arg95 Arg83 Arg79 Arg61
Lys123 Lys113 Lys123 Lys145 Lys140 Lys134 Tyr105
His125 His115 His125 His147 His142 His136 Thr107
Sulfate binding His181 His211 His229 His242 His236 His290 His218
Arg282 Lys375 Lys302 Lys318 Lys310 Lys368 Lys337
† The identity of the divalent cation was later demonstrated to be Ca2+ in ASA structures with PDB codes 1n2k and 1n2l
(Chruszcz et al., 2003).
aminoglycan substrates heparan sulfate and heparin at the
nonreducing terminus of the linear GAG chain. In analogy
with the enzymatic reaction mechanism previously proposed
for O-sulfatases (Boltes et al., 2001; von Bu¨low et al., 2001), we
suggest that the substrate is first desulfated while sulfating the
enzyme, which is then desulfated in turn (Fig. 5). Specifically,
an activated O atom, O2, from the hydrated form of
formylglycine attacks the sulfur centre of the N-linked sulfate
group of the substrate, resulting in a covalently bound
enzyme–substrate complex with a pentavalent sulfur in the
transition state. In this step, the activation of the hydroxyl O
atom involves transfer of its proton to a base, with a potential
candidate being Asp273. An acidic group then facilitates the
breakage of the S—N bond by protonating the N atom to form
an amine leaving group. The N-desulfated substrate diffuses
away, leaving an O-sulfated enzyme. Finally, a base (possibly
His125) deprotonates the second C hydroxyl group of
formylglycine, resulting in the formation of a double bond
between the O atom and the C atom. While the bridging C—
O bond to the sulfate group breaks, the sulfate ion
is eliminated and the formylglycine residue is regenerated.
The enzyme is now ready for another round of catalysis.
The identity of the acid that facilitates the breakup of the
transition state with concomitant desulfation of the substrate
is uncertain, with candidates suggested for PAS including
Lys375, His211, the second hydroxyl group of FGly via the
sulfate, or a water molecule. The species that act as the acid
could plausibly change as a function of solution pH (Boltes
et al., 2001). The role of His211 as the acid has also been
suggested by a recent density functional theory-based
quantum-mechanical study based on the PAS structure (PDB
entry 1hdh; Marino et al., 2013). The residue corresponding to
His211 is conserved in the other sulfatases, including SGSH
(His181; Table 2). In order to identify plausible interactions
in the active site, we generated an in silico docking model of
nonphosphorylated SGSH derived from the present study
with the substrate monosaccharide 2-N-sulfoglucosamine
(Fig. 6). In this model, His181 is located close to the N atom of
the leaving amine, at the site of the cleaved S—N bond. His181
would be expected to be protonated at the lysosomal pH and
thus appears to be a good potential candidate proton donor in
the catalytic mechanism of SGSH.
The lysine equivalent to Lys375 in PAS is structurally
conserved in all of these O-sulfatases, including BcPMH.
However, in SGSH the lysine is replaced by an arginine
(Arg282; SGSH numbering). The side chain of Arg282 forms
salt bridges in the active site with Asp32 and Asp399, which
are located 7.6 A˚ apart on opposite sides of this arginine
(Fig. 2d). An arginine at this position appears to be conserved
in many putative sulfamidase sequences closely homologous
to SGSH (Supplementary Fig. 11). Furthermore, arginine has
been shown to interact up to 2.5 times more strongly with
heparin than does lysine (Stenlund et al., 2002; Fromm et al.,
1995). In the docking model mentioned above, the side chain
of Arg282 lies close to one of the sulfate O atoms and the
3-hydroxyl O atom of the substrate, apparently orienting the
substrate for catalysis. Taken together, these structural data
suggest an important binding role for Arg282 in SGSH. The
functional and structural effects resulting from the substitu-
tion of arginine by lysine will be investigated using an
Arg282Lys SGSH mutant in the future.
Since our structural data cannot completely describe the
reaction partners involved, we are unable to exclude an
alternative reaction mechanism in which one of the sulfate O
atoms attacks the C atom (Bond et al., 1997).
4.3. Enzyme inhibition
Phosphate buffer was used in the purification of SGSH.
Difference density next to FGly70 in the active site could be
modelled as a covalently bound phosphoryl group. However,
based on our data we are unable to exclude that this is a
covalently bound sulfate group. Sulfate and phosphate have
both been found to inhibit arylsulfatase A from rabbit liver
(Lee & Van Etten, 1975) and human N-acetylgalactosamine-
6-sulfatase (Bielicki et al., 1995). Sulfate has previously been
shown to be a strong inhibitor of SGSH (Freeman &
Hopwood, 1986). We found phosphate to be a more potent
inhibitor of SGSH than sulfate, which supports the building of
a phosphorylated FGly70 in the present structure.
4.4. Molecular basis of disease-causing mutations
The correlation of genotype with phenotype has often been
difficult in MPS IIIA, with attendant difficulties in diagnosis
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Figure 4
Superposition of the SGSH backbone on those of five related sulfatases:
SGSH (red), ASA (orange), ASB (yellow), PAS (blue), GALNS (green)
and BcPMH (brown). SGSH shares a common fold with O-sulfatases
consisting of a large central -sheet with decorating helices (‘conserved
region’, top); the loops form a more variable region (‘nonconserved
region’, bottom). For orientation, the SGSH N-terminus and C-terminus
are shown (N and C, respectively), as are some secondary-structure
elements (as in Fig. 2a) and some atoms in the active site in ball
representation: Ca2+ (dark grey), phosphate O atoms (orange), FGly C
(light grey) and free hydroxyl O atom (red).
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: CB5050).
and prognosis (Di Natale et al., 1998; Yogalingam&Hopwood,
2001). Suggested explanations include genetic heterogeneity
and difficulty in phenotypic classification, especially in a
disease in which mental and behavioural symptoms typically
dominate the clinical picture. Genetic, epigenetic and envir-
onmental modulating factors might further contribute to
the phenotypic variability in MPS IIIA (Beesley et al., 2000;
Di Natale et al., 1998; Perkins et al., 1999). Except for two
relatively small regions of high-homology sulfatase consensus-
sequence regions (residues 70–80 and 115–124), SGSH in
general shares only a low sequence identity with O-sulfatases
for which atomic structures have been described. As a result,
understanding the molecular basis of the disease has been
especially difficult for this enzyme.
In Table 3, we list 80 disease-causing missense mutations
that have been described in SGSH and briefly describe the
predicted structural effects of these mutations based on the
atomic structure of the enzyme determined in the present
study. Fig. 7 displays these mutations as mapped onto the
three-dimensional structure of the SGSH monomer. Most
missense mutations for which disease severity has been
reported in MPS IIIA patients are associated with a rapidly
progressing, early-onset form of the disease (Di Natale et al.,
2003). Approximately a quarter of the mutations affect surface
residues. In the case of two mutations that affect buried resi-
dues but are associated with a late-onset phenotype, namely
E292K and S298P, it appears plausible that the presence of
buried waters in the wild-type genotype acts as an amelior-
ating factor by offering substitution space for the mutated side
chain.
Three of the mutations (D32G, D32E and D273N) affect
buried Ca2+-binding residues. While D32G and D273N lead to
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Figure 5
Proposed reaction mechanism in SGSH (schematic). The active-site formylglycine (FGly70), which is intrinsically reactive, undergoes hydration to form
the resting state of the enzyme with a gem-diol group (step 1). Coordination of one of the hydroxyl groups of the gem-diol to a Ca2+ ion facilitates the
development of a negative charge on the O atom as its proton is lost to a base. The negatively charged O atom nucleophilically attacks the sulfur centre of
the N-linked sulfate group on the glucosamine substrate (step 2), resulting in a covalently bound enzyme–substrate complex with a pentavalent sulfur
transition state. An acid (possibly His181) facilitates the cleavage of the S—N bond by protonating the bridging N atom to form an amine leaving group
on the N-desulfated substrate, which diffuses away, leaving an O-sulfated enzyme (step 3). Finally, in a step that underlines the importance of the
formylglycine residue, another base (His125) deprotonates the second hydroxyl group, resulting in a negatively charged O atom (step 4) that forms a
double bond with the C atom as the C—O bond between it and the bridging O atom of the sulfate group breaks, eliminating the sulfate ion and
regenerating the formylglycine residue (step 5).
an early-onset disease phenotype, the conservative substitu-
tion D32E is associated with late-onset disease, presumably
owing to a partly retained Ca2+-binding capability.
4.4.1. Common mutations. Significant regional variations in
the frequency of particular mutations have been described in
MPS IIIA patients. Thus, R74C occurs in 56% of disease
alleles in Polish patients, 50% of those in patients from
Finland and Estonia and 21% of those in patients from
Germany (Bunge et al., 1997). Arg74 is identified in the
present structure as a buried active-site residue that forms
hydrogen bonds to FGly70 and salt bridges with the Ca2+-
binding Asp31 and Asp273. A structural comparison with
SGSH homologues with known atomic structures shows that
it is strictly conserved in all of them, including BcPMH, which
otherwise shows only a loose conservation of five of the ten
important active-site residues (Table 2). Mutations affecting it
would be predicted to impair enzyme function, likely including
its stability, resulting in an early-onset disease phenotype,
which has been observed for both mutations that affect this
residue (R74C and R74H).
S66W is associated with an early-onset disease phenotype. It
is the most common mutation observed in Italy, occurring in
33% of disease alleles (Di Natale et al., 1998). Replacement of
the buried Ser66 by the bulky aromatic residue tryptophan is
likely to disrupt packing in a five-residue loop immediately
preceding a helix (2) housing active-site residues, including
FGly70.
Another common mutation, R245H, is also associated with
an early-onset phenotype and has been described in up to
57.8% of patients from the Netherlands, 35% of disease alleles
from German patients and 20% of those from patients in the
UK (Beesley et al., 2000; Weber et al., 1997; Bunge et al., 1997).
The arginine side chain is not typically buried. However, in
SGSH the side chain of Arg245, which lies in the middle of the
long helix 7, makes a buried salt bridge with Asp179 and
hydrogen bonds to Asp179 and Phe197. A histidine in its place
would be too bulky at the base and too short, thus tending to
destabilize the local structure and packing. This interpretation
is consistent with the lack of enzyme activity that has been
reported for this mutation (Perkins et al.,
1999).
4.4.2. Mutations and the dimer interface.
Active SGSH has been shown to be a dimer
(Freeman & Hopwood, 1986; Paschke &
Kresse, 1979). Ten chains of SGSH mono-
mers found in the two crystal forms in the
current study associate to form five homo-
dimers. Residues forming the dimer inter-
face were clearly identified. One of the
missense mutations directly affects a residue
at the dimer interface, namely V486F. Its
replacement by the bulky aromatic pheny-
lalanine would lead to a steric clash, desta-
bilizing the dimer interface. The mutation
has been shown to be associated with an
early-onset disease phenotype.
Additionally, it has consistently been
observed that nonsense mutations in the
SGSH gene are associated with an early-
onset disease phenotype (Yogalingam &
Hopwood, 2001). The enzyme structure
offers a rational molecular explanation.
Many residues involved in dimer formation
not only belong to the C-terminal domain 2
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Figure 7
Stereo figure showing missense mutations mapped onto the structure of the SGSH monomer.
C atoms of residues associated with an early-onset phenotype are shown in red, those
associated with an intermediate-onset phenotype in blue and those associated with a late-onset
phenotype in yellow. Missense mutations for which the phenotype was not reported are
indicated in grey. Most mutations with known phenotype are early-onset mutations. Late-onset
mutations appear to map closer to the periphery of the enzyme. Some of the most common
mutations are indicated by a larger ball size. These are Ser298, Arg245 (indicated ‘1’), Arg74
(‘2’), Ser66 (‘3’) and Gln380. The orientation shown is the same as for one of the subunits (on
the left) of the dimer in Fig. 2(b); the active site is indicated by FGly70 (stick model; standard
colours) and Ca2+ ion (black ball). Glycosylations are shown as green sticks.
Figure 6
Hypothetical model showing some proposed interactions between the
terminal N-sulfoglucosamine residue (GlcNS; C atoms in green, other
atoms in standard colours) of the substrate with the enzyme in the active
site (C atoms in light grey). His181 acts as the acid facilitating desulfation
of the substrate. Other residues that help to bind and orient the substrate
include the side chains of FGly70, Lys123, Arg282 and His368 and the
main-chain amide N atom of Asp401.
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Table 3
Missense point mutations in SGSH and their expected effect based on the atomic structure of SGSH.
Abbreviations: NR, not reported; Interm., intermediate; sc, side chain, H bond, hydrogen bond; NASA, normalized accessible surface area per atom per residue
(as a percentage of the maximal value for any internal residue in SGSH).
Protein Codon Phenotype NASA Type Effect of mutation on structure Reference
M1V 1A>G NR Signal peptide Part of signal peptide Pollard et al. (2013)
L12Q 35T>A Late Signal peptide Part of signal peptide Valstar et al. (2010)
A30P 88G>C NR 0 Buried Steric clash close to Ca2+-binding site; loss of H bond to
Thr271
Pollard et al. (2013)
D32G 95A>G Early 1 Metal binding Disruption of Ca2+ binding Beesley et al. (2000)
D32E 96C>A/G Late 1 Metal binding Altered Ca2+ binding Meyer et al. (2008)
G33R 97G>A NR 4 Buried Introduces bulky sc next to Ca2+-binding Asp32 Pollard et al. (2013)
Y40N 118T>A Interm. 13 Surface Loss of H bonding to Leu294 and Phe60, and of -stacking
interactions; next to glycosylation site
Di Natale et al. (1998)
N42K 126C>A Early 6 Surface Loss of H bonding to Ala44, Ile45 and Tyr240; steric clash Lee-Chen et al. (2002)
A44T 130G>A Early 31 Surface Steric clash at surface site Di Natale et al. (1998), Esposito et al.
(2000)
S66W 197C>G Early 2 Buried Introduction of bulky sc in buried position in loop close to
active site
Blanch et al. (1997), Weber et al. (1997),
Di Natale et al. (1998), Montfort et al.
(1998), Beesley et al. (2000), Chaba´s
et al. (2001), Piotrowska et al. (2009),
Valstar et al. (2010), Muschol et al.
(2011), Pollard et al. (2013)
R74C 220C>T Early 0 Buried Disruption of ion pairs/H bonds with Ca2+-binding Asp31,
FGly70 and Asp273; possible interference with disulfide-
bridge formation
Bunge et al. (1997), Weber et al. (1997),
Di Natale et al. (1998), Beesley et al.
(2000), Esposito et al. (2000), Emre et
al. (2002), Muschol et al. (2004, 2011),
Meyer et al. (2008), Piotrowska et al.
(2009), Valstar et al. (2010), Pollard et
al. (2013)
R74H 221G>A Early 0 Buried Disruption of ion pairs/H bonds with Ca2+-binding Asp31,
FGly70 and Asp273
Bunge et al. (1997), Chaba´s et al. (2001)
T79P 235A>C Early 0 Buried Disruption of H bonding to Ala75, Ser76 and Leu81 Weber et al. (1997), Beesley et al.
(2000), Pollard et al. (2013)
H84Y 250C>T Early 1 Buried Loss of H bond to Ser364 and Thr475; steric clash in buried
position
Beesley et al. (2000)
Q85R 254A>G Early 3 Buried Steric clash Montfort et al. (1998), Chaba´s et al.
(2001)
M88T 263T>C NR 0 Buried Destabilizes van der Waals interactions in buried position;
steric clash
Fiorentino et al. (2006)
G90R 268G>A Early 0 Buried Gain of bulky sc in buried position; change of / angles Bunge et al. (1997), Piotrowska et al.
(2009)
S106R 318C>A Late 0 Buried Loss of H bond to Leu109, Val131; clash possibly accom-
modated within longer, partially surface-exposed loop
Muschol et al. (2004)
T118P 352A>C NR 0 Buried Loss of H bonds to Asp135; destabilizes -sheet Zhang & Huiping (2008)
G122R 364G>A Interm. 1 Buried Bulky sc in buried position; Gly ’/ angles Bunge et al. (1997), Di Natale et al.
(1998), Beesley et al. (2000), Valstar
et al. (2010), Pollard et al. (2013)
P128L 383C>T Late 22 Surface Favourably surface-exposed to minimize steric clash; in loop
with FGly-binding His125 and Lys123
Di Natale et al. (1998, 2003)
V131M 391G>A Early 1 Buried Bulky sc in buried position; destabilizes loop with FGly-
binding residues
Weber et al. (1997)
T139M 416C>T Early 1 Buried Bulky sc in buried position; loss of H bond to Glu141 Weber et al. (1997)
L146P 437T>C Early 11 Surface Loss of H bond to Ser144; some clash at surface; destabilizes
helix 5; close to glycosylation site (Asn151)
Di Natale et al. (1998)
R150W 448C>T Early 1 Buried Introduction of bulky aromatic sc; loss of salt bridge with
Asp179, H bonding to His181
Beesley et al. (2000), Chaba´s et al.
(2001)
R150Q 449G>A Early 1 Buried Loss of ion pair with Asp179, H bonding to His181; next to
glycosylated Asn151
Bunge et al. (1997), Di Natale et al.
(1998), Chaba´s et al. (2001), Valstar
et al. (2010), Montfort et al. (1998)
L163P 488T>C Early 8 Buried Disruption of hydrophobic interactions, H bond to Val159;
clash; destabilizes helix 6
Muschol et al. (2004)
D179N 535G>A Early 1 Buried Loss of buried salt bridges with Arg150, Arg245 Di Natale et al. (1998), Esposito et al.
(2000)
P180L 539C>T Late 0 Buried Some steric clash next to active site-residues Asp31 and
His181
Valstar et al. (2010)
R182C 544C>T Interm. 4 Buried Loss of ion pair with Asp235, H bond to Pro277 close to active
site; possible interference with disulfide-bridge formation
Di Natale et al. (1998), Valstar et al.
(2010)
G191R 571G>A Early 11 Surface Surface-exposed but steric clash with scs of Glu195 and
Lys196; Gly ’/ angles
Muschol et al. (2004), Valstar et al.
(2010)
F193L 579C>G NR 0 Buried Disrupts -stacking next to active-site loop (His181) Bunge et al. (1997), Yogalingam &
Hopwood (2001)
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Table 3 (continued)
Protein Codon Phenotype NASA Type Effect of mutation on structure Reference
R206P 617G>C Late 73 Surface Suface-exposed; Arg206 has no backbone amide H bond to
lose; close to glycosylated Asn151; change in ’/ angles
Montfort et al. (1998), Esposito et al.
(2000), Chaba´s et al. (2001), Gabrielli
et al. (2005)
P227R 680C>G Early 0 Buried Steric clash from bulky substitution disrupts packing in buried
position
Di Natale et al. (1998), Esposito et al.
(2000)
A234G 701C>G Early 51 Surface Unclear; possibly destabilization of helix 7 Weber et al. (1997)
D235N 703G>A Early 1 Buried Loss of buried salt bridge with Arg182 and of H-bond
acceptor
Beesley et al. (2000), Lee-Chen et al.
(2002)
D235V 704A>T NR 1 Buried Loss of buried salt bridge with Arg182 and of H bonds to
Thr192 and Thr407
Bunge et al. (1997)
T242T 726C>T NR 0 Buried Unclear Valstar et al. (2010)
R245H 734G>A Early 0 Buried Loss of buried salt bridge with Asp179 and H bonds to
Asp179 and Cys194; clash; packing of helix 7
Blanch et al. (1997), Bunge et al. (1997),
Weber et al. (1997, 1998), Beesley et
al. (2000), Muschol et al. (2004, 2011),
Meyer et al. (2008), Valstar et al.
(2010), Pollard et al. (2013)
D247H 739G>C NR 1 Buried Loss of H bonding to Leu50; clash Valstar et al. (2010)
G251A 752G>C Late 13 Surface Some clash with sc of His49 in surface-exposed site Meyer et al. (2008), Muschol et al.
(2011)
D273N 817G>A Early 2 Metal binding Disrupts Ca2+ binding Beesley et al. (2000)
Y286S 857A>C NR 4 Buried Disruption of H bond to Glu437 and of -stacking
interactions
Yogalingam & Hopwood (2001)
P288S 862C>T Early 5 Buried Possibly unsatisfied H bonding in sc of Ser in buried position Emre et al. (2002)
P288L 863C>T NR 5 Buried Steric clash Pollard et al. (2013)
E292K 874G>A Late 0 Buried Buried water might offer space to accommodate larger sc Piotrowska et al. (2009)
P293T 877C>A NR 3 Buried Steric clash; loss of Pro from three-residue loop Di Natale et al. (2006)
P293S 877C>T Early 3 Buried Unclear; loss of Pro from three-residue loop Lee-Chen et al. (2002), Pollard et al.
(2013)
S298P 892T>C Late 1 Buried Loss of H bonds to Glu300, His301, but steric clash milder as
buried water offers substitution space; favourable ’/ 
angles (Ser297, Ser298)
Bunge et al. (1997), Beesley et al.
(2000), Muschol et al. (2004, 2011),
Meyer et al. (2008), Valstar et al.
(2010), Pollard et al. (2013)
E300V 899A>T Early 48 Surface Unclear; loss of surface salt bridge with Arg23; little steric
clash
Bekri et al. (2005)
R304L 911G>T NR 7 Surface Loss of surface salt bridge with Glu355 and of H bonds to
Ala351 and Gln307; some steric clash
Di Natale et al. (2006), Pollard et al.
(2013)
Q307P 920A>C Early 38 Surface Loss of surface H bonds to Arg304; steric clash;
destabilization of strand 8
Bekri et al. (2005)
A311D 932C>A NR 3 Buried Steric clash; buried charge; unsatisfied H bonding Pollard et al. (2013)
D317H 949G>C NR 4 Buried Steric clash; loss of H bonds to Ser314, Arg346 Pollard et al. (2013)
T321A 961A>G NR 0 Buried Loss of H bonds to Asp317, Leu348 and of van der Waals
interactions
Bunge et al. (1997)
I322S 965T>G Late 0 Buried Loss of van der Waals interactions, but I322S can H-bond to
Leu318
Beesley et al. (2000)
S347Y 1040C>A NR 15 Surface Bulky aromatic in solvent-exposed position, but with minimal
steric clash; loss of H bonds to Asp324, Leu349
Valstar et al. (2010)
S347F 1040C>T Late 15 Surface Bulky aromatic in solvent-exposed position, but with minimal
steric clash; loss of H bonds to Asp324, Leu349
Miyazaki et al. (2002)
A354P 1060G>C Early 58 Surface Loss of H bond to Pro350; steric clash with Pro350; change in
’/ angles
Montfort et al. (1998), Chaba´s et al.
(2001)
E355K 1063G>A Early 39 Surface Loss of surface salt bridge with Arg304 and of H bonds to
Ser309, Glu310; charge switch
Beesley et al. (2000)
S364R 1092C>G NR 1 Buried Loss of H bonds to Gln83 and His84; marked steric clash in
buried position
Bunge et al. (1997)
E369K 1105G>A Early 6 Surface Loss of H bond to Gln400; charge switch close to active site Di Natale et al. (1998, 2003), Esposito et
al. (2000), Valstar et al. (2010),
Pollard et al. (2013)
Y374H 1120T>C Early 2 Buried Unsatisfied H bonding; charge Beesley et al. (2000)
R377C 1129C>T Early 0 Buried Loss of buried salt bridge with Asp477 and of H bonds to
Ser366, Met376; plausibly interference with disulfide-
bridge formation
Di Natale et al. (1998), Lee-Chen et al.
(2002)
R377H 1130G>A Early 0 Buried Loss of buried salt bridge with Asp477 and of H bonds to
Ser366, Met376
Weber et al. (1997), Yogalingam &
Hopwood (2001), Bunge et al. (1997),
Valstar et al. (2010)
R377L 1130G>T NR 0 Buried Loss of buried salt bridge with Asp477 and of H bonds to
Ser366, Met376
Pollard et al. (2013)
Q380R 1139A>G Early 2 Buried Gain of charge in buried position close to surface; steric clash
may affect H bond to Arg382
Weber et al. (1997), Valstar et al. (2010)
L386R 1157T>G Early 0 Buried Introduction of charge and steric clash in buried position;
disruption of hydrophobic interactions
Montfort et al. (1998), Chaba´s et al.
(2001)
V387M 1159G>A NR 2 Buried Bulky residue in buried position Di Natale et al. (2006)
but also lie in close proximity to the C-terminus, including
Leu487, Glu488, Pro497, Leu498 and the third-last residue
Asn500. Nonsense mutations where even a relatively minor
part of domain 2 is missing may be predicted to be destabi-
lizing to the dimer interface. Since part of the access to the
active-site pocket is formed by the second subunit in the
dimer, this would be likely to affect the binding of heparin and
heparan sulfatate and thus disrupt enzyme function.
4.5. Prospects
The wild-type structure provides a rational basis for
understanding the effects of many mutations. It may be useful
in predicting the phenotype of mutations of unreported
phenotype or as yet unknown genotype. Although it is
possible to envisage significant divergence from the wild-type
structure in some mutations, the low structural flexibility of
SGSH suggests a promising effect of molecular chaperones
in the cases of many missense mutations (Boyd et al., 2013).
Molecular chaperones that bind to the active site and recon-
stitute its structural architecture might be promising at first
hand. In addition, small molecules with allosteric or stabilizing
effect may be beneficial in the cases of mutations located more
distantly from the active site or at the SGSH surface. In vitro
studies that test for the rescue of SGSH activity may be the
initial step to evaluate structure-based chaperones before
clinical trials can further prove the effectiveness of these small
molecules. Additionally, the SGSH structure will be very
useful for the engineering of SGSH variants or fusion proteins
with beneficial biological features that increase its therapeutic
effectiveness in enzyme-replacement therapy and other
treatment modalities (Sly & Vogler, 2013; Sorrentino et al.,
2013).
5. Conclusions
The structure of SGSH determined to 2.0 A˚ resolution clearly
extends our understanding of the molecular pathology
underlying MPS IIIA and thus lays the groundwork for the
development of the structure-based rational design of general
and mutation-specific therapeutic tools such as molecular
chaperones. In addition, the crystal structure provides
fundamental atomic-level knowledge for protein modifica-
tions, with the aim of facilitating the transport of SGSH across
the blood–brain barrier. Chemically synthesized protein
modifications or genetically engineered fusion proteins can
enter the brain via endogenous receptor-mediated endocytosis
of the attached ligand (Pardridge, 2007). Since the brain is the
organ most severely affected in MPS IIIA, cerebral delivery is
absolutely crucial for successful treatment of this devastating
disorder.
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